Completed PHASE3 INTERVENTIONAL 2-arm NCT02430259

Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention

Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China

Sponsor: Huashan Hospital

Conditions Silicosis Tuberculosis

Interventions Weekly INH / RRT given by DOT

Updated 7 times since 2017 Last updated: Jun 27, 2020 Started: Mar 31, 2015 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Silicosis and Tuberculosis, this trial is completed. The trial is conducted by Huashan Hospital and has accumulated 7 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2019 — Jul 2020 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Huashan Hospital

Data source: Huashan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taizhou, China